Bioventix PLC (FRA:51B)

Germany flag Germany · Delayed Price · Currency is EUR
18.00
-0.20 (-1.10%)
At close: Feb 20, 2026
Market Cap98.73M -47.2%
Revenue (ttm)15.30M -3.6%
Net Income8.85M -6.3%
EPS1.67 -6.3%
Shares Outn/a
PE Ratio11.16
Forward PE11.97
Dividend1.72 (9.39%)
Ex-Dividend DateNov 6, 2025
Volumen/a
Average Volume4
Open18.30
Previous Close18.20
Day's Range18.00 - 18.30
52-Week Range17.70 - 37.40
Betan/a
RSI36.48
Earnings DateMar 25, 2026

About Bioventix

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. It offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; Pyrene 1-hydroxypyrene glucuronide (HOP-G) ELISA kit to monitor human exposure to industrial pollutants; and Pyrene (HOP-G) lateral flow kits for monitoring of at-risk individuals without laboratory equipment. The company also provides contract SMAs services; and industrial and environ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2003
Employees 12
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 51B
Full Company Profile

Financial Performance

In fiscal year 2025, Bioventix's revenue was 13.12 million, a decrease of -3.61% compared to the previous year's 13.61 million. Earnings were 7.58 million, a decrease of -6.33%.

Financial numbers in GBP Financial Statements